Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanethidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanethidine SCHEMBL28254486 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8000929 | 1.00 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL3128359 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL22127050 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL15514378 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28128869 | 0.98 | CA12 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL10310276 | 0.98 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL22127049 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL28081160 | 0.93 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| Guanethidine SCHEMBL11873662 | 0.91 | CA12 (0.47) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8538 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260076976-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-12396998-B2 | Treatment for heart failure with preserved ejection fraction with guanethidine and guanadrel | M2SP LLC (US) | 2025-08-26 | — | — | US | claimed |
| EP-4590307-A1 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | M2SP LLC (US) | 2025-07-30 | — | — | EP | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| EP-0047339-B1 | DRUG FOR THE LOCAL TREATMENT OF GLAUCOMA | Dr. Thilo & Co. GmbH (DE) | 1984-02-08 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4415564-A | TOPICAL AQUEOUS SOLUTIONS OF GUANETHIDINE AND TERBUTALINE | DISPERSA AG (CH) | 1983-11-15 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0069075-A1 | Pharmaceutical preparation for treating glaucoma and ocular hypertension | DISPERSA AG (CH) | 1983-01-05 | — | — | EP | claimed |
| EP-0005057-A1 | A material and composition for reducing blood pressure | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | claimed |
| US-4164570-A | FOR TOPICAL TREATMENT OF GLAUCOMA | CLOUGH DAVID (GB) | 1979-08-14 | — | — | US | claimed |
| US-4163054-A | PHENYL HYDRAZINO SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR AND GUANETHIDINE | MERCK & CO., INC. (US) | 1979-07-31 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |